markably cross-resistant to vinblastine (280-fold), paclitaxel (2400-fold), and doxorubicin (47-fold) but not cisplatin, suggesting a multidrug-resistant phenotype. Supporting this hypothesis, MCF7/MDR cells were 10-fold cross-resistant to disorazole C 1 . HeLa/DZR disorazole resistance was not durable in the absence of chronic compound exposure. Verapamil reversed HeLa/DZR resistance to disorazole C 1 and disorazole A 1 . Moreover, HeLa/DZR cells expressed elevated levels of the drug resistance ATP-binding cassette ABCB1 transporter. Loss of ABCB1 by incubation with short interfering RNA restored sensitivity to the disorazoles. Thus, the multidrug resistance transporter ABCB1 can affect the cytotoxicity of both disorazole C 1 and A 1 . Disorazole C 1 , however, retained activity against cells resistant against the clinically used microtubulestabilizing agent epothilone B.
The myxobacterium Sorangium cellulosum has been a rich source of pharmacologically interesting secondary metabolites, including the clinically used semisynthetic analog of epothilone B ixabepilone (Chin et al., 2006) . Disorazole polyene macrodiolides were isolated first in 1994 and observed to have significant antifungal activity with no antibacterial activity (Jansen et al., 1994) . Initial biochemical and pharmacological studies focused on the major fermentation product disorazole A 1 , which blocks cell proliferation, causes G 2 /M phase arrest and loss of microtubules, and induces apoptosis (Elnakady et al., 2004; Kopp et al., 2005) . More recently, we synthesized and explored the actions of the minor fermentation component, disorazole C 1 , in part because it lacked the reactive epoxide found on disorazole A 1 (Supplemental Fig.  1 ). Remarkably, disorazole C 1 has potent antiproliferative activity against a wide variety of human tumor cells, it disrupts cellular microtubule integrity, it blocks microtubule polymerization in vitro, it binds tubulin in a unique manner, and it causes apoptosis and premature cellular senescence, all attributes associated with a promising anticancer agent (Wipf and Graham, 2004; Wipf et al., 2006; Tierno et al., 2009) .
Disorazole resistance has not been extensively studied; the limited existing literature suggests the natural product disorazole A 1 is not a substrate for the ABCB1 multiple drug resistance transporter (Elnakady et al., 2004) . To help clarify further the actions of the disorazoles and the biochemical factors that might impart resistance to their pharmacological actions, we attempted to generate tumor cells that were resistant to their growth inhibitory properties.
Our initial efforts to establish resistant cell populations by exposing cells to stepwise increased concentrations of disorazole C 1 were unsuccessful (Tierno et al., 2009 ). In the current study, we have successfully made the first disorazole-resistant cell population using a combination of single step chemical mutagenesis and multistep exposure to increasing concentrations of disorazole C 1 . These cells displayed a multidrug-resistant phenotype and overexpressed the ABCB1 transporter. Use of chemical inhibitors or small interfering RNA against the ABCB1 transporter restored growth inhibition by disorazole C 1 . Significantly, disorazole C 1 retained growth inhibitory activity against epothilone B-resistant cells.
Materials and Methods
Cell Culture Reagents and Proliferation Assays. HeLa, MCF7, MCF7/MDR, A549 (ATCC, Manassas, VA), and epothilone B-resistant A549/EpoB40 cells (a gift from Susan Band Horwitz, Albert Einstein College of Medicine) were cultured in the Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (Cellgro, Mediatech, Herndon, VA). The A549/ EpoB40 cells were grown in the presence of 40 nM epothilone B, and 24 h before experimental use the medium was removed, cells were detached with 0.05% trypsin/EDTA, and the washed cells were replated in epothilone B-free medium. Disorazole C 1 was synthesized as described previously (Wipf and Graham, 2004) . Unless otherwise indicated, all media, sera, and supplements were obtained from Invitrogen (Carlsbad, CA), and other reagents were from SigmaAldrich (St. Louis, MO).
Inhibition of growth was determined using our previously described method (Vogt et al., 2004 (Vogt et al., , 2008 . In brief, we fixed cells in 3.7% formaldehyde and stained nuclei with 2 g/ml Hoechst 33342 dye to quantify cells using an ArrayScan VTi imaging cytometer (Thermo Fisher Scientific, Waltham, MA) (Vogt et al., 2004 (Vogt et al., , 2008 . The 50% growth inhibitory concentration (IC 50 ) of a test agent was calculated after a 72-h incubation. For all studies cells were continuously exposed to compounds in complete medium.
Development of the HeLa/DZR Subline. HeLa cells at 90% confluence were mutagenized by a 24-h exposure to 4 mM ethyl methane sulfonate in DMEM without fetal bovine serum. Cells were rinsed twice with sterile phosphate-buffered saline, once with complete DMEM, and then allowed to recover for 5 days in complete DMEM. Resistant cells were selected by a stepwise increase in the concentration of disorazole C 1 over a period of 9 months. Cells (90% confluent) were first exposed for 24 h to 100 pM disorazole C 1 in complete DMEM. After rinsing twice with sterile phosphate-buffered saline and once with complete DMEM, the cells were allowed to recover in complete DMEM until they reached 90% confluence. The cells were then treated with increasing concentrations of disorazole C 1 (ϳ300 pM/treatment cycle), washed, and allowed to recover again. Cells were periodically tested for increased resistance to disorazole C 1 compared with wild-type HeLa cells. Resistance was quantified by comparing IC 50 values of the mutagenized, disorazole-treated cells with those of wild-type HeLa cells. Stepwise increase of disorazole C 1 treatment was stopped at 10.8 nM with a level of ϳ30-fold resistance. To maintain resistance, HeLa/DZR cells were exposed to 10.8 nM disorazole C 1 every 2 weeks and then rinsed and allowed to recover as described above. A revertant cell line (HeLa/DZR/Rev) was developed by culturing HeLa/DZR cells for 32 passages without exposure to disorazole C 1 .
Verapamil Reversal. Wild-type HeLa and HeLa/DZR cells were seeded in 96-well plates at a density of 1500 cells per well and allowed to attach overnight. After attachment, cells were incubated for 72 h in the presence or absence of 5 M verapamil with various concentrations of disorazole C 1 , disorazole A 1 , and vinblastine. Cells jpet.aspetjournals.org were then fixed with 3.7% formaldehyde, and nuclei were stained with 2 g/ml Hoechst 33342 dye to quantify cells using an ArrayScan VTi imaging cytometer as described previously (Vogt et al., 2004 (Vogt et al., , 2008 .
siRNA Knockdown of ABCB1. Three unique siRNA duplexes targeting ABCB1 were obtained from Invitrogen: ABCB1HSS107917 sequences (5Ј-3Ј) GAGUGGGCACAAACCAGAUAUAUU and AA-UAUUAUCUGGUUUGUGCCCACUC; ABCB1HHSS107918 sequences CCAUAAAUGUAAGGUUUCUACGGGA and UCCCGUA-GAAACCUUACAUUUAUGG and AACUUGACCAGCAUCGG; and ABCB1HSS107919 sequences GCUCGCCAAUGAUGCUGCUCAAGUU and AACUUGAGCAGCAUCAUUGGCGAGC. HeLa/DZR cells were transfected with 20 nM ABCB1 siRNA or scrambled (Stealth siRNA Negative Control Hi GC; Invitrogen) siRNA as follows: HeLa/DZR cells were plated at a density of 7.5 ϫ 10 4 cells/well into a six-well tissue culture plate in antibiotic-free EMEM. The next day, three wells each were transfected with 20 nM ABCB1 siRNA or scrambled siRNA using 5 l/well Dharmafect 1 reagent (Dharmacon RNA Technologies, Lafayette, CO) and 480 l/well Opti-MEM transfection medium (Invitrogen) in a total volume of 2 ml/well. Dharmafect and siRNAs were preincubated separately in half the final volume of Opti-MEM for 5 min before being combined in an RNase-free tube and coincubated for 20 min. Antibiotic-free EMEM was then added to a final volume of 2 ml/well. Culture medium was removed from the cells and replaced with the medium containing transfection reagents. Five hours later, this medium was removed and replaced with complete EMEM. After 24 h, cells were detached with 0.05% trypsin, seeded into 96-well plates at a density of 1000 cells/well, and allowed to attach overnight. For some studies, cells were treated 48 h after transfection with compounds and growth inhibition determined 72 h later.
Western Blotting. To determine relative ABCB1 expression, we allowed HeLa, HeLa/DZR, HeLa/DZR/Rev, MCF7, and MCF7/MDR cells to grow almost to confluence in six-well plates and then harvested them in ice-cold lysis buffer (50 mM Tris, pH 7.6, containing 150 mM NaCl, 1 mM EDTA, 0.1% SDS, and 1% Triton X-100) supplemented with protease and phosphatase inhibitors as described previously (Achiwa and Lazo, 2007) . Protein concentrations in cell lysates were determined with the bicinchoninic acid protein assay kit (Promega, Madison, WI). Equivalent protein amounts from cell lysates were resolved on 6 or 8% Tris glycine gels (Invitrogen) and transferred to nitrocellulose membranes via iBlot. ABCB1 and ␤-tubulin expression were detected by Western blotting with the ABCB1 antibody (C-19), and the ␤-tubulin antibody (CLT9003; Cedarlane Laboratories, Burlington, ON, Canada). As a control for ABCB1 protein, we used MES-SA/Dx5 cell lysate from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). To determine the protein depletion by siRNA, we transfected HeLa/DZR cells with siRNA duplexes targeting ABCB1 (Stealth Select RNAi; Invitrogen) or scrambled siRNA negative control at concentrations of 20 and 40 nM. After 24 to 72 h, cells were lysed and analyzed by Western blot as described above using ␤-tubulin as the loading control.
Results
Development of Disorazole C 1 -Resistant Cells. We initially treated exponentially growing wild-type human HeLa or A549 cells with various concentrations of disorazole C 1 , attempting to harvest compound-resistant surviving cells, but this proved nonproductive. Thus, we adopted a traditional single step mutagenesis compound selection strategy. HeLa cells were treated for 24 h with 4 mM ethyl methane sulfonate, and after washing with DMEM cells were allowed to recover for 5 days in complete DMEM. Resistant cells were selected by a stepwise increase in the concentration of disorazole C 1 over a period of 9 months. The resulting HeLa/DZR cells had a disorazole C 1 IC 50 value of 5.1 nM compared with an IC 50 value of 0.15 nM for the wild-type HeLa cells (34-fold resistance; Fig. 1 ). The disorazole A 1 IC 50 values for HeLa and HeLa/DZR cells were 0.05 and 0.40 nM (8.4-fold resistance), respectively. Surprisingly, the HeLa/ DZR cells displayed a higher cross-resistance to vinblastine, doxorubicin, and paclitaxel relative to HeLa cells: 279-, 47-and 2408-fold, respectively (Fig. 1) . We found no cross-resistance to cisplatin, indicating that the resistance did not extend to all cytotoxic chemotherapeutic agents.
Disorazole C 1 -Resistant Cells Overexpress ABCB1 and Loss of ABCB1 Restores Sensitivity to Disorazoles. Because of the resistance profile in HeLa cells, we next examined the disorazole sensitivity of naive cells that previously had not been treated with disorazole but expressed elevated levels of the drug transporter ABCB1. MCF7/MDR cells had significantly more ABCB1 than MCF7 cells and were 10-fold more resistant to disorazole C 1 than MCF7 cells ( Fig. 2A) . These ABCB1-overexpressing cells were 79-fold resistant to vinblastine, as expected (Fig. 2B) .
We noted during the development of the HeLa/DZR cells that disorazole C 1 resistance required repeated biweekly exposures to low (10.8 nM) concentrations of disorazole C 1 to enforce the resistant phenotype. We next determined the stability of the resistance phenotype by culturing HeLa/DZR cells for 32 passages without exposure to disorazole. This led to a revertant cell line called HeLa/DZR/Rev, which was almost as sensitive to disorazole C 1 as the parental HeLa cells (Fig. 3A) . The HeLa/DZR/Rev also lacked any significant resistance to vinblastine (Fig. 3B) . These results indicate that the disorazole C 1 -resistant phenotype developed in HeLa/DZR cells was reversible.
Disorazole C 1 -Resistant Cells Have a Phenotype That Is Similar to ABCB1-Overexpressing Cells. Because the HeLa/DZR cells exhibited a drug resistance profile reminiscent of classical multidrug resistant cells, we next examined the effect of a classical reversing agent, verapamil, on the growth inhibition caused by disorazole C 1 , disorazole A 1 , and vinblastine (Fig. 4) . Cotreatment of HeLa/DZR cells with verapamil caused a complete reversal of resistance to disorazole C 1 , whereas the growth inhibitory effects of disorazole C 1 with HeLa cells were unaffected (Fig. 4A) . Similar results were found with disorazole A 1 (Fig. 4B) . Verapamil also sensitized HeLa/DZR and HeLa cells to vinblastine (Fig.  4C) . These results suggest that the disorazole-resistant cells might overexpress one of the major contributors of a multidrug resistant phenotype: ABCB1.
Disorazole C 1 -Resistant Cells Overexpress ABCB1 and Loss of ABCB1 Restores Sensitivity to Disorazole C 1 . We next examined the disorazole-resistant cells for expression of ABCB1. As illustrated in Fig. 5A , lane 2, the ABCB1 protein levels in HeLa/DZR cells were markedly elevated, exceeding those in the well characterized MES-SA/ Dx5 cells (Fig. 5A, lane 4) . Significantly, ABCB1 levels in the HeLa/DZR/Rev cells were comparable with the levels found in the parental HeLa cells (Fig. 5A, lanes 1 and 3) . To further evaluate the role of ABCB1 in disorazole resistance, we transiently suppressed ABCB1 levels in HeLa/DZR cells with siRNA (Fig. 5B) . We found 20 and 40 nM siRNA caused a Ͼ75% reduction in ABCB1 protein levels after 24-to 72-h exposure (Fig. 5B, lanes 2 and 3) . HeLa/DZR cells regained complete sensitivity to disorazole C 1 after treatment with ABCB1 siRNA (Fig. 6A) , although the transfection process appeared to cause partial sensitization in that the cells treated with scrambled siRNA were slightly more responsive to disorazole C 1 than the untreated cells. HeLa/DZR cells were also sensitized to disorazole A 1 by ABCB1 siRNA. In addition, it is interesting to note that these cells were not affected by scrambled siRNA (Fig. 6B) . Although HeLa/DZR cells were sensitized to vinblastine by ABCB1 siRNA, the sensitization was not complete (Fig. 6C) . In contrast, ABCB1 siRNA had no effect on the cisplatin sensitivity of HeLa/DZR (Fig. 6D) .
Epothilones are the most recently FDA-approved and clinically used microtubule-targeting anticancer agents. Despite their size and functional group complexity, these natural product-based agents are generally believed to be unaffected by ABCB1 (Bollag et al., 1995) . Epothilone-resistant cells, however, are cross-resistant to another common clinically used natural product, which is affected by ABCB1: paclitaxel jpet.aspetjournals.org (Fig. 7B) . Therefore, we examined the sensitivity of epothilone-resistant cells to disorazole C 1 . The Epo40 cells were ϳ100-fold resistant to epothilone B (Fig. 7A ) and ϳ20-fold resistant to paclitaxel (Fig. 7B) . In contrast Epo40 cells were not cross-resistant to disorazole C 1 (Fig. 7C ).
Discussion
The highly electrophilic divinyl oxirane moiety of disorazole A 1 has been observed to be a potent inhibitor of tubulin polymerization, and it induces apoptosis at low concentrations, i.e., Ͻ100 pM (Elnakady et al., 2004) . Our previous studies indicated that the bioactive disorazole pharmacophore does not require the divinyl oxirane moiety. Disorazole C 1 represents one family member that retains considerable potency to inhibit tubulin polymerization and antiproliferative activity against a large number of human tumor cells, but it also is obtainable by synthetic chemistry (Wipf and Graham, 2004; Tierno et al., 2009) . Moreover, disorazole C 1 appears to exploit a unique binding mechanism to disrupt microtubule integrity and causes senescence (Tierno et al., 2009) . Our attempts to generate disorazole-resistant cells met with considerable difficulties. We ultimately used both mutagenesis and stepwise exposure to increasing concentrations of disorazole C 1 . Furthermore, the resulting resistant population was not stable.
The only previous study examining potential disorazole resistance, albeit minimally, suggested cells overexpressing ABCB1 might not be resistant to disorazole A 1 (Elnakady et al., 2004) . Elnakady et al. (2004) used a multidrug-resistant KB cell line with elevated ABCB1 produced by increased stepwise exposure to vinblastine. They observed the KB-V1 cells were only 2-fold resistant to disorazole A 1 , whereas were 13-fold resistant to vinblastine (Elnakady et al., 2004) . Treatment of KB-V1 cells with 11 M verapamil increased sensitivity 2-fold against disorazole A 1 , while multiplying vinblastine sensitivity 100-fold. Thus, it was surprising to find that the disorazole C 1 -resistant cells we generated were crossresistant to anticancer agents often associated with multiple drug resistance derived from high ABCB1 expression. Furthermore, we found that both the disorazole C 1 -resistant cells and MCF7 with elevated ABCB1 were resistant to disorazole A 1 . Our siRNA and pharmacological results support the hypothesis that at least a portion of the disorazole C 1 and A 1 resistance in HeLa/DZR was due to ABCB1. We recognize the methodology used to generate the disorazole C 1 -resistant cells could cause other alterations that could produce resis- tance and these should be studied in the future. Nonetheless, it would appear that at least one protein, ABCB1, can yield cellular resistance to the disorazole pharmacophore. We have no adequate explanation for why resistance was not observed previously with the KB model. It is possible the differences reside in the selected cell type and further studies are required to address this question.
The disorazole pharmacophore remains a potent and promising platform for the development of novel anticancer agents. It is notable that disorazole C 1 retained activity against epothilone-resistant cells, which could be one attribute for stimulating additional studies on this unique natural product pharmacophore. Efforts should be extended to remove sensitivity to the ABCB1 transporter.
